Table 5 Comparison of selected previous series evaluating ART versus SRT

n

BCRFS

p

Included tumors

BCR-criteria

Budiharto et al. [15]

ART: 130

5-years: 87% (95%-CI: 77–98%)

<0.001*

pT2-T4, N0, R0/R1

Not available

SRT: 89

5-years: 34% (95%-CI: 11–56%)

Jereczek-Fossa et al. [27]

ART: 258

4-years: 81.7%

<0.0001*

pT2-T4, N0, R0/1

(I) Post-RT PSA level nadir plus 0.1 ng/mL, or any PSA level greater than the pre-RT PSA level

(II) Salvage-ADT

SRT:173

4-years: 60.5%

Briganti et al. [16]

ART: 390

2-years: 91.4%

5-years: 78.4%

0.9

pT3, N0, R0/1

Post-RT PSA level >0.2 ng/mL and rising

SRT: 225

2-years: 92.8%

5-years: 81.8%

Ost et al. [28]

ART: 144

3-years: 90%

0.002*

pT2-T4, N0, R0/1

Increase of more than 0.2 ng/mL above lowest post-OP PSA value

SRT: 134

3-years: 65%

Mishra et al. [29]

ART: 74

5-years: 84%

10-years: 73%

0.0001*

pT2, N0, R1 or pT3-T4, N0

For patients with undetectable pre-RT PSA: ≥0.4 ng/mL with a subsequent confirmation.

For all other patients:

(I) Three documented increases measured at least 6 weeks apart

(II) Start of ADT

SRT: 122

5-years: 55%

10-years: 41%

Detti et al. [30]

ART: 203

BCR at time of analysis 20.7%,

0.03*

pT2-T4, N0, R0/1

Two consecutive measurements >0.2 ng/mL, measured at least 30 days apart.

SRT: 104

BCR at time of analysis: 31.7%

n

MFS

p

Included tumors

Metastasis-criteria

Fossati et al. [31]

ART: 243

8-years: 92% (95%-CI: 87–93%)

0.9

pT3–4, N0, R0/1

Distant metastases in bones, parenchymal organs, or soft tissue.

SRT: 267

8-years: 91% (95%-CI: 84–95%)